title: Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery.
abstract: This article summarizes efforts to evaluate poly(amido amine) (PAMAM) dendrimers as carriers for oral drug delivery. Specifically, the effect of PAMAM generation, surface charge and surface modification on toxicity, cellular uptake and transepithelial transport is discussed. Studies on Caco-2 monolayers, as models of intestinal epithelial barrier, show that by engineering surface chemistry of PAMAM dendrimers, it is possible to minimize toxicity while maximizing transepithelial transport. It has been demonstrated that PAMAM dendrimers are transported by a combination of paracellular and transcellular routes. Depending on surface chemistry, PAMAM dendrimers can open the tight junctions of epithelial barriers. This tight junction opening is in part mediated by internalization of the dendrimers. Transcellular transport of PAMAM dendrimers is mediated by a variety of endocytic mechanisms. Attachment or complexation of cytotoxic agents to PAMAM dendrimers enhances the transport of such drugs across epithelial barriers. A remaining challenge is the design and development of linker chemistries that are stable in the gastrointestinal tract (GIT) and the blood stream, but amenable to cleavage at the target site of action. Recent efforts have focused on the use of PAMAM dendrimers as penetration enhancers. Detailed in vivo oral bioavailability of PAMAM dendrimer-drug conjugates, as a function of physicochemical properties will further need to be assessed.
authors: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, USA.
authors: S
authors: S
authors: Sadekar
authors: H
authors: H
authors: Ghandehari
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001692:Biological Transport; D050091:Dendrimers / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007413:Intestinal Mucosa / Q000378:metabolism*; D019108:Tight Junctions / Q000187:drug effects / Q000378:metabolism
chemical_list: D000277:Adjuvants, Pharmaceutic; D050091:Dendrimers; C104700:PAMAM Starburst